By Ikon Kim
May 22, 2026 · 4 min readState treasuries, tech billionaires, and venture funds funneled billions of dollars into anti-aging research over the past year, even as bioethicists and stem-cell scientists warn that the clinical evidence still trails the marketing.
The convergence of state science budgets, Silicon Valley investments, and dedicated longevity funds marks a shift from fringe biohacking toward a mainstream healthspan race, with policy and regulatory frameworks racing to catch up.
Russia committed $26.4 billion to a New Technologies for Health Preservation national project launched in 2025 under direct instruction from President Vladimir Putin, according to The Moscow Times.
The Institute of Aging Biology and Medicine targets the RAGE receptor, a cellular switch that, when active, accelerates aging and, when blocked, may prolong cellular youth, with Russian production planned between 2028 and 2030.
Deputy Prime Minister Tatyana Golikova previously said, "What some time ago we could describe as an incredible future is now becoming reality," Golikova said earlier.
The project's senior figures include Deputy Prime Minister Tatyana Golikova and Kurchatov Institute head Mikhail Kovalchuk.
Putin himself, now 73, frames longevity as both a national priority and a personal one, given that average Russian male life expectancy hovers around 67.
In Washington, Health and Human Services Secretary Robert Kennedy Jr. brought an entourage of wellness entrepreneurs into federal health policy, according to KFF Health News.
Calley Means co-founded Truemed, his sister Casey Means co-founded the glucose-monitoring firm Levels, and informal adviser Gary Brecka markets longevity protocols through a sprawling podcast operation.
Kennedy and four MAHA allies collected at least $3.2 million from the wellness industry in the years before joining the administration, according to ethics filings the outlet reviewed.
Private capital tells a similar story, with British crypto entrepreneur Will Harborne launching the LongGame fund to deploy $40 million over four years into biotech startups targeting the root causes of aging.
Initial portfolio companies include ImmuneAge, Vincere Bio, Adaptyv Bio, and Zero Health, with former Buck Institute researcher Manish Chamoli advising the fund as chief scientific officer.
The science itself spans a wide range of maturity, according to the 2026 Science Breakthrough Radar, an annual longevity-medicine survey from the Geneva-based GESDA Foundation.
Some interventions, such as senolytic drugs and GLP-1 weight-loss medications, have reached mid-stage human trials, while gene therapies and cellular reprogramming remain closer to early-lab work, even as a separate cluster of stem-cell infusions and gene therapies already sells to paying clients in offshore clinics without large-scale safety data.
The radar drew on input from 2,390 researchers across 89 countries, framing biological aging as a modifiable risk factor on par with smoking or hypertension.
ETH Zurich neuroscientist Nicole Wenderoth and EPFL Paul Marks Prize winner Andrea Ablasser anchor the radar's roster, alongside a University of Zurich omega-3 study that slowed epigenetic clocks by several months.
Epigenetic clocks read chemical marks on DNA to estimate biological age, and a slower reading suggests that cells age more gradually than calendar years.
The boom has produced a dark side too, with longevity tourism flourishing in jurisdictions where regulators wave through experimental gene therapies that the FDA would block, Slate reported in March 2026.
Minicircle, a Honduras-based gene-therapy startup operating from the charter city Próspera on Roatán, sells follistatin gene therapy at $25,000 per injection to clients, including biohacker Bryan Johnson.
OpenAI chief executive Sam Altman provided early funding to Minicircle, illustrating how Silicon Valley capital flows directly into the same offshore clinics that bypass standard drug-approval pathways.
University of California, Irvine bioethics professor Leigh Turner dismissed the broader sector as overhyped marketing with weak underlying evidence.
Stanford stem-cell researcher Irving Weissman published peer-reviewed work failing to confirm the existence of certain embryonic-like cells that several clinics market as a rejuvenation tool.
The political and clinical lines blur further: Kennedy, now overseeing the U.S. health bureaucracy, admitted in June 2025 to receiving an experimental stem-cell therapy at an offshore clinic.
Regulators worldwide now face the same dilemma: how to police an industry that markets immortality while running on cellular biology. No court has yet certified safety at scale.
The race itself shows no sign of slowing, with state treasuries, billion-dollar venture pools, and Silicon Valley fortunes all betting that someone, somewhere, will finally crack the biology before the lawsuits arrive.
Ikon Kim
Grade 11
St. Mark’s School
